• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Molecular Characterization of in vivo Adjuvant Activity in Influenza-Vaccinated Ferrets

tetano

Editor, Senior Moderator
J Virol. 2010 Jun 9. [Epub ahead of print]
Molecular Characterization of in vivo Adjuvant Activity in Influenza-Vaccinated Ferrets.

Fang Y, Rowe T, Leon AJ, Banner D, Danesh A, Xu L, Ran L, Bosinger SE, Guan Y, Chen H, Cameron CC, Cameron MJ, Kelvin DJ.

Division of Immunology, International Institute of Infection and Immunity, Shantou University Medical College, 22 Xinling Road, Shantou, Guangdong, P.R. China, 515041; Division of Experimental Therapeutics, Toronto General Research Institute, University Health Network, 101 College Street, Toronto, Ontario, Canada, M5G 1L7; Department of Immunology, University of Toronto, Toronto, Ontario, Canada; University di Sassari, Dipartimento di Scienze Biomediche, Sassari,, Italy; Division of Virology, International Institute of Infection and Immunity, Shantou University Medical College, 22 Xinling Road, Shantou, Guangdong, P.R. China, 515041; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract

The 2009 H1N1 influenza pandemic has prompted a significant need for the development of efficient, single-dose adjuvanted vaccines. Here we investigated the adjuvant potential of CpG Oligodeoxynucleotide (ODN) when used with human seasonal flu vaccine in ferrets. We found that CpG ODN-adjuvanted vaccine effectively increased antibody production and activated type I interferon (IFN) responses, compared to vaccine alone. Based on these findings, pegylated IFN-alpha2b (PEG-IFN) was also evaluated as an adjuvant in comparison to CpG ODN and Complete Freund's Adjuvant (CFA). Our results showed that all three adjuvant-added vaccines prevented seasonal human H1N1 Brisbane59 virus replication more effectively than vaccine alone. Gene expression profiles indicated that, as well as up-regulating IFN-stimulated genes (ISGs), CpG ODN enhanced B cell activation and increased TLR4 and IRF4 expression, whereas PEG-IFN augmented adaptive immunity by inducing MHC transcription and Ras signaling. In contrast, using CFA as an adjuvant induced limited ISG expression but increased the transcription of MHC, cell adhesion molecules, and B cell activation markers. Taken together, our results better characterize the specific molecular pathways leading to adjuvant activity in different adjuvants-mediated flu vaccination.

PMID: 20534862 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/20534862
 
Back
Top Bottom